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Highlights 1 
This systematic review found that: 2 
 Average number of drugs per prescription met optimal levels for all World Bank regions 3 
except Latin America and the Caribbean. 4 
 Improvement needed in percentage of antibiotics prescribed per prescription in all regions 5 
of the world. 6 
 There is no country where the percentage of drugs prescribed by generic name is at optimal 7 
levels. 8 
 Average consultation time of physicians was below the optimal value (≥10 minutes) except 9 
for Europe and Latin America. 10 
 The percentage of drugs dispensed and availability of essential drugs was close to optimal 11 
except in Europe and Latin America. 12 
 13 
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 20 
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 22 
 23 
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ABSTRACT 7 
Objectives: Standard drug use indicators have been developed by the World Health 8 
Organization/International Network for Rational Use of Drugs (WHO/INRUD). The objective 9 
of this systematic review was to evaluate, and report the current status of drug use within health 10 
systems in different regions of the world. 11 
Design: Systematic review of the literature following PRISMA guidelines.  12 
Methods: The INRUD bibliography, WHO archives, Google Scholar, Medline, PubMed, 13 
SpringerLink, ScienceDirect and Management Sciences for Health (MSH) resource databases 14 
were searched between 1985 and 2015 for studies containing 12 WHO/INRUD core drug use 15 
indicators. Secondary data sources were also searched.  16 
Results: Four hundred and sixty three studies were retrieved and 398 were excluded as they 17 
did not provide relevant information or fulfill the selection criteria. Sixty articles met the 18 
criteria and were selected for final review. With respect to prescribing indicators, studies of 19 
“drug use” showed mixed patterns across geographic regions. Overall trends in “patient-care” 20 
and “facility-specific” indicators were similar across most of the World Bank regions. 21 
4 
 
However, based on the Index of Rational Drug Use (IRDU) values, East Asia and the Pacific 1 
region demonstrated relatively better drug use practices compared with other regions. 2 
Conclusions: This systematic review revealed that the drug use practices in all regions of the 3 
world are suboptimal. A regulated, multi-disciplinary, national body with adequate funding 4 
provided by governments throughout the world is a basic requirement for coordination of 5 
activities and services, in-order to improve the rational use of drugs at a local level. 6 
Keywords:  Prescribing indicators, Patient-care indicators, Facility-specific indicators, World 7 
Bank regions, Income level, Rational drug use. 8 
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INTRODUCTION 1 
Medicines are the single most common therapeutic intervention and a crucial component 2 
of medical care for any healthcare system [1]. According to the World Bank, in developing 3 
countries, 20–50% of the health care expenditures are spent on drugs and other medical products 4 
[2]. The appropriate use of drugs is essential for optimizing individual patient health and the 5 
population health of any nation [3]. In 1985, the World Health Organization (WHO) organized a 6 
conference to promote the rational use of drugs [4]. Since then, efforts have been augmented to 7 
improve drug use, particularly in under-developed as well as developing countries [5]. According 8 
to the WHO, the rational use of drugs requires that patients receive drugs appropriate to their health 9 
problems, in optimal doses for correct duration at minimum cost to individuals and the nations’ 10 
health system [2, 6, 7]. There are numerous factors that influence rational prescribing for example; 11 
the medical state of patients, beliefs, values and prescribing behaviour of physicians, the working 12 
environment within the health system, the drug supply system, legislation, and information 13 
available about the drugs [8-12]. 14 
Irrational prescribing of drugs by doctors and suboptimal drug use by patients is a global 15 
problem. Studies have shown that worldwide over 50% of all drugs are prescribed or sold 16 
incorrectly, and 50% of patients do not use drugs optimally [2]. Inappropriate prescribing practices 17 
and irrational use of drugs can result in unsafe and ineffective treatment resulting in morbidity and 18 
mortality and harm and distress to patients Increases in out-of-pocket expenses for patients and a 19 
general waste of resources also occurs [2, 13]. In low and middle income countries, these problems 20 
are exacerbated by restrained economic resources and lack of regulated drug policies [14]. 21 
According to published studies, poly-pharmacy, inappropriate antibiotic use, overuse of injectable 22 
drugs, use of prescription drugs inconsistent with clinical guidelines, and less than optimal self-23 
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medication are the major reasons for irrational drug use [2]. The increase in resistance due to the 1 
overuse of antibiotics is a considerable problem of irrational drug use [2, 15]. Irrational drug use 2 
has also been reported to reduce patients’ confidence in their own health care systems [2].  3 
Essential Drugs List (EDL) promotes efficient and effective use of medicines. The choice 4 
of essential drugs is complex and the needs of the population must be considered as part of the 5 
selection process. This is specifically with respect to diagnosis, prophylaxis, treatment (therapy) 6 
and rehabilitation using parameters of the risk-to-benefit ratio, quality and practical management, 7 
cost effectiveness, and patient acceptance and compliance [8, 9, 16]. Approximately one-third of 8 
the world's population does not have access to essential drugs [2] either because they are not 9 
included in the EDL, or key drugs on the EDL are not available at the time of prescribing. 10 
Previous studies have shown that drug use practices are less than optimal [16]. To better 11 
understand pattern of drug use and to allow quantification and comparison through systematic 12 
means, standardized drug use indicators have been developed by the World Health 13 
Organization/International Network for Rational Use of Drugs (WHO/INRUD) [3]. To-date, these 14 
standard drug use indicators have been successfully used in developing countries for performance 15 
management and process improvement [3, 17, 18].  16 
The purpose of this systematic review was to examine and report the current status of health 17 
facilities in different regions of the world in terms of drug use based on WHO/INRUD core drug 18 
use indicators [2] (see Table 1). A review article [19] and a fact book published by the WHO [20] 19 
reports the results based on data available up to 2009. The contribution that this current systematic 20 
review makes is in the detailed description of patient-care and facility-specific indicators and 21 
presentation of evidence that results in greater generalizability of individual indicators within a 22 
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variety of World Bank regions. This paper also uses published indices [15, 21, 22] to compare the 1 
rational use of drugs within different regions of the world. This systematic review provides useful 2 
information for researchers, administrators, policymakers and other important stakeholders to 3 
evaluate existing patterns of drug utilization at global, national, regional and local levels. 4 
Furthermore, this review informs the formulation of educational interventions, national drug 5 
policies and National Essential Drugs Lists (NEDL), as well as hospital formularies, in-order to 6 
improve prescribing patterns and the cost-effective use of drugs. 7 
< Insert Table 1 here > 8 
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METHODS 1 
Published studies and scientific reports containing 12 WHO/INRUD core drug use 2 
indicators were systematically identified for the period 1st January 1985 to 31st December 2015. 3 
Studies from developed, developing and transitional countries that presented drug use data were 4 
extracted. A systematic review ensured complete collection of literature. The PRISMA guidelines 5 
[23] were followed [Appendix 1: PRISMA Checklist]. 6 
Search strategy 7 
A systematic search strategy was implemented using WHO archives, Google Scholar, 8 
Medline, PubMed, SpringerLink, ScienceDirect and Management Sciences for Health (MSH). 9 
Search terminologies included: “Drug use indicators”, “WHO/INRUD”, “Prescribing indicators”, 10 
“Patient-care indicators”, “Facility-specific indicators” and “Prescribing behavior” which were 11 
used in diverse combinations with BOOLEAN and MeSH search methods. In addition, all studies 12 
available in the conference proceedings of the Third International Conference for Improving Use 13 
of Medicines (held in Turkey, 2011), were reviewed and included in the search for completeness 14 
[24]. Appropriate secondary data sources were also sourced [19, 20, 25]. Initially, 463 studies were 15 
identified and retrieved. Of these, 106 were duplicates that were excluded. From the remaining 16 
357 articles, over half (169) were excluded based on having irrelevant titles and/or ambiguous 17 
content. Subsequently, the full text of 188 articles was read and 123 studies were removed at this 18 
point due to failure to provide relevant information. Constructive disagreement amongst the 19 
research team regarding study eligibility was resolved through discussion and mutual agreement 20 
within team meetings. Sixty five articles made the final selection (Figure 1) based on criteria 21 
outlined in Table 2. Three reviewers SS, MRS and MAZ systematically searched the studies from 22 
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the INRUD bibliography, whilst two independent reviewers checked all studies to verify the 1 
validity of screening processes. All authors agreed to include these final studies in the review. 2 
<Insert Figure 1 here> 3 
< Insert Table 2 here > 4 
Data entry 5 
A purpose designed data extraction form was used for data entry. Each record described; 6 
drug use patterns in countries based on classification by geographical and income level in World 7 
Bank regions. A maximum of three studies per country were selected regardless of the number 8 
available. Studies were selected which included all standard indicators (or a maximum number) of 9 
the most recent ones. A careful literature search revealed that there are a good number of INRUD 10 
indicator studies available from counties like China, India, and Ethiopia etc. Contrary to this, only 11 
a few studies were available from European countries. Therefore, to maintain uniformity in the 12 
data, the researchers developed a criterion that if more than three studies were available from a 13 
single country, then a maximum of three of the most recent studies reporting the maximum number 14 
of INRUD indicators would be included in the review.  15 
All data was entered then rechecked before being exported into Statistical Package for 16 
Social Sciences (SPSS v 21.0) and Microsoft Excel 2010 for analysis.  17 
Analysis 18 
Descriptive statistics were used to analyze the data. In this systematic review the primary 19 
outcome measures were the 12 commonly reported WHO/INRUD indicators as outlined in Table 20 
10 
 
1. The optimal values for prescribing [13], patient-care and facility-specific indicators [15, 21] 1 
were adopted from previous studies.  2 
The median value for each indicator was calculated based on the total number of studies in 3 
each geographic region according to the World Bank regional classification, as well as the income 4 
level classification of the countries analyzed. To assess the rational use of drugs, summary indices 5 
were calculated: Index of Rational Drug Prescribing (IRDP), Index of Rational Patient-Care Drug 6 
Use (IRPCDU) and Index of Rational Facility-Specific Drug Use (IRFSDU). These indices were 7 
developed by employing a validated mathematical model derived by Zhang and Zhi (1995) [26]. 8 
This is an established model for developing indices that has been well cited with respect to the 9 
drug prescribing indicator literature in developing nations including China, Saudi Arabia, United 10 
Arab Emirates, Egypt, Pakistan, Sierra Leone, Zambia and Ethiopia [15, 21, 27-32]. For the 11 
calculation of indices (index of non-polypharmacy, index of rational antibiotic use and index of 12 
safe injection drug use), the following formula was used; 13 
𝐼𝑛𝑑𝑒𝑥 =
Optimal value
Observed value
 14 
All other indices (index of generic name, index of EDL, consultation time index, 15 
dispensing time index, index of drugs actually dispensed, index of labeling of drugs, index of 16 
patients’ knowledge, index of EDL availability and index of key drug availability in stock) were 17 
calculated using the following formula; 18 
𝐼𝑛𝑑𝑒𝑥 =
Observed  value
Optimal value
 19 
The maximum value for each of the indices was 1. The close the value to 1 the better the 20 
performance for that indices. The Index of Rational Drug Use (IRDU) was calculated by summing 21 
the IRDP, IRPCDU, and IRFSDU. The World Bank regions (geographic and income level) were 22 
11 
 
ranked based on the IRDU and the regions with the highest IRDU value were considered to be 1 
performing the best and so; were ascribed a rank of 1. 2 
12 
 
RESULTS 1 
Core drug use indicators by World Bank regions  2 
Table 3 outlines studies of prescribing indicators by geographic origin. The majority of 3 
studies were undertaken in Sub Saharan Africa, followed by South Asia, East Asia and the Pacific, 4 
the Middle East and North African regions, respectively. Very few studies have been conducted 5 
in Europe and Central Asia, or Latin America and the Caribbean regions.  6 
Findings from this internationally focused systematic review suggest a mixed picture of 7 
prescribing patterns across various geographic regions (Table 3). Studies from East Asia and the 8 
Pacific region point towards positive performance in this region, with the highest percentage of 9 
drugs prescribed from an EDL/formulary, and the highest percentage of generic prescribing. 10 
Studies from Latin America and the Caribbean region had the lowest number of drugs per 11 
prescription and the lowest number of antibiotics. The percentage of injections prescribed per 12 
prescription was similar when comparing all the regions.  13 
< Insert Table 3 here > 14 
Table 4 shows the studies from different countries that measured patient-care and facility-15 
specific indicators in different settings by geographic location. Because of the smaller number of 16 
studies, the data from Europe and Central Asia, and Latin America and Caribbean regions is 17 
merged into one group.  18 
This systematic review suggests that overall trends in patient-care and facility-specific 19 
indicators were similar when comparing all regions of the world (Table 4). Low average 20 
consultation times as well as dispensing times were observed in all regions of the world except for 21 
13 
 
Europe and Latin America, and South Asia. Studies from East Asia and the Pacific region reported 1 
the highest percentage of drugs actually dispensed, the highest proportion of patients with correct 2 
knowledge of drug doses, the highest percentage of EDL availability and the highest percentage 3 
of key drugs in stock at the time of prescribing. Studies from South Asia reported the highest 4 
percentage of adequate labeling. 5 
< Insert Table 4 here > 6 
Core drug use indicators by World Bank income level regions 7 
Figures 2 and 3 present the overall results of the core drug use indicators by World Bank 8 
income level regions. This systematic review indicates disparities in prescribing patterns across 9 
regions [Additional file: WHO/INRUD indicators by World Bank income level]. Studies from 10 
high income level countries report the lowest percentage of patients prescribed antibiotics and 11 
injectable and the highest percentage of drugs prescribed from an EDL/formulary. The generic 12 
prescribing rate per prescription was highest for the low income countries which also report the 13 
lowest number of drugs per encounter. 14 
< Insert Figure 2 here > 15 
< Insert Figure 3 here > 16 
With respect to patient-care indicators, studies from high income level countries showed 17 
the highest average consultation and dispensing times, along with the greatest percentage of drugs 18 
actually dispensed [Additional file:  WHO/INRUD indicators by World Bank income level]. 19 
Studies from lower-middle and upper-middle income level countries report the highest percentage 20 
of patients with knowledge of the correct doses and the highest percentage of adequate labeling, 21 
respectively. Similarly, with reference to facility-specific indicators, low income level countries 22 
14 
 
had the highest percentage of EDL availability and the highest percentage of key drugs in stock 1 
[Appendix 2:  WHO/INRUD indicators by World Bank income level]. 2 
Summary indices 3 
Table 5 summarizes the overall results of the core drug use indicators in terms of indices; IRDP, 4 
IRPCDU, and IRFSDU. 5 
< Insert Table 5 here > 6 
 7 
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DISCUSSION 1 
The irrational use of drugs exists all over the world and ultimately can lead to unwanted 2 
effects in most patients [15]. In this systematic review, we identified current treatment practices in 3 
different regions of the world using established indicators. This is expected to help prioritize 4 
interventions for improving drug use practices, and the evaluation of the outcome of these 5 
interventions. Our findings provide useful baseline information for future monitoring and 6 
assessments of the rational use of drugs in the international context. 7 
Prescribing indicators 8 
The results of this review show that the average number of drugs per prescription was 9 
above optimal levels for all World Bank classified regions except for Latin America and the 10 
Caribbean. This is an important finding as poly-pharmacy leads to escalated risk of drug 11 
interactions [92], prescribing errors [93], reduced compliance [35], possible adverse effects, and 12 
wastage of drugs. This leads ultimately to increased hospital costs [94], as well as fiscal 13 
implications for the health-care system. Evidence-based clinical guidelines such as prescribing 14 
policies and standard treatment guidelines are crucial for promoting the rational use of drugs as 15 
they help prescribers in making appropriate clinical decisions [2]. This study supports an increased 16 
focus on this.  17 
The percentage of antibiotics prescribed per prescription in these studies suggests that 18 
improvement is needed in all regions of the world. Misuse and over-prescribing of antibiotics is a 19 
common global problem with potentially dire circumstances. One of the important manifestations 20 
of irrational use of antibiotics is the higher probability of antibiotic resistance developing [15]. 21 
This review suggests that the percentage of encounters for which an injectable dosage form is 22 
16 
 
prescribed is optimal all over the globe, except in Sub Saharan Africa (Table 3). An excessive use 1 
of injections when oral formulations are available is not cost-effective nor clinically inappropriate 2 
[2] because patients are more likely to suffer from blood borne diseases such as Hepatitis C and 3 
HIV [15] and there is no obvious increase in clinical benefit 4 
This international review suggests that nowhere in the world is the percentage of drugs 5 
prescribed by generic name, at optimal levels. This suggests that practice is not in accordance with 6 
policy; the WHO guidelines for rational prescribing [92]. The situation is most alarming in the 7 
Middle East and North Africa, as well as in high income level countries; although in high-income 8 
countries it may be less of an issue with drug availability and affordability being potentially 9 
greater. Non-generic prescribing practices suggests that there is room for reducing national 10 
pharmaceutical expenditure; particularly in the developing world Interventions that reduce the 11 
significant influence of originator brand pharmaceutical companies on medical prescribers should 12 
be thought about. The main advantages of generic prescribing are lower treatment costs and the 13 
avoidance of prescription and dispensing errors that may arise due to “look-alike” or “sound-alike” 14 
brand names [95]. The WHO deems generic prescribing to be a safety measure for patients as the 15 
process allows professionals to clearly depict the drug name and also allows easily accessible 16 
information about the drug, and leads to less ambiguous communication among health care 17 
providers [15].  18 
Unlike with generic prescribing, the percentage of drugs prescribed from EDL/formulary 19 
was seen to be almost optimal in most regions except Europe and Central Asia (Table 5). Drugs 20 
included in EDL are older, tested in practice, low cost and have established clinical use [15]. 21 
Furthermore, a smaller number of drugs in EDL makes inventory management less complicated. 22 
17 
 
Similarly, there is less chance of medication errors by prescribers and pharmacists, because access 1 
to the appropriate knowledge and information is available for a smaller number of drugs [2].  2 
Patient-care indicators 3 
This systematic review suggests that the average consultation time of the physicians for all 4 
regions ranged from 2.3 to 7.3 minutes, which was below the optimal value ≥10 minutes except 5 
for Europe and Latin America where it was 14.2 minutes (Table 4). According to the WHO, a 6 
shorter consultation time is inadequate in-order to conduct a complete patient examination, that is; 7 
to conduct proper history taking, complete physical examination, appropriate health education, 8 
sound physician-patient interaction and to prescription of therapy [15]. The short consultation time 9 
reported in all regions could be the result of a large number of patients to be examined per 10 
physician. Similarly, the average dispensing time was also not optimal for all regions of the world 11 
(Table 5). The short dispensing time is insufficient to provide complete information to patients 12 
about dosage regimen, unwanted drug effects, precautions and checking for adequate labeling and 13 
dispensing of drugs. The optimal dispensing time may relate to patient compliance through the 14 
information provided and knowledge gained about drugs, which is a primary step in improving 15 
patient care. 16 
The percentage of drugs actually dispensed was close to the optimal index for most regions 17 
except Europe and Latin America (Table 5). An inadequate drug supply will lead to the use of non-18 
essential drugs that will ultimately cause an increase in out-of-pocket expenses for patients. It will 19 
have a negative impact on patients’ health status, convenience and trust of the health care system 20 
[2]. The WHO recommends that each dispensed drug should be adequately labeled including the 21 
patient’s name, dose of the drug and dosage regimen [3]. At the same time, patient knowledge 22 
18 
 
about the correct dosage is highly influential in promoting treatment adherence. The findings from 1 
this systematic review reveal that drug labeling practices were sub-optimal throughout the world 2 
(Table 5). Moreover, patients did not have the correct drug dosage knowledge. Omission of the 3 
patient’s name on the product label is a serious issue that has significant consequences including 4 
drug misuse and abuse. Similarly, without satisfactory knowledge about the risks and benefits of 5 
drugs and an understanding of proper dosage regimens, patients might not achieve expected 6 
clinical results [2]. 7 
Facility-specific indicators 8 
The percentage of availability of EDL/formulary listed drugs was close to the optimal index 9 
for most regions except Europe and Latin America. However, the percentage of key drugs in stock 10 
at the time of prescribing was found to be below the optimal index. Shortage of essential drugs is 11 
disadvantageous as it leads to prescribing more costly drugs from the open market. According to 12 
the WHO, physicians should be adherent to prescribing the drugs listed in the EDL/formulary. At 13 
the same time, concerned authorities at a government level must ensure the availability of essential 14 
drugs at health care facilities.  15 
CONCLUSION AND RECOMMENDATIONS 16 
The results of this systematic review reveal that irrational drug use practices are occurring 17 
in all regions according to World Bank classification. Irrational utilization of drugs may lead to 18 
increased adverse effects, increased morbidity and mortality, greater wastage of resources and 19 
higher out-of-pocket expenses for patients. Based on this review the authors recommend that 20 
continuous education and training of physicians is needed to reinforce rational prescribing. This is 21 
particularly with regards to antibiotics, injectable, generic medicines and prescribing from an EDL. 22 
19 
 
The patient-to-physician ratio should be decreased to allow for prolongation of consultation time, 1 
which allows thorough history taking, comprehensive examination and sound therapeutic 2 
relationships between patients and physicians. This should also be the case to ensure sound drug 3 
dispensing and improvement of patient knowledge through increased duration of counselling 4 
sessions. Availability of key drugs in stock should be improved to ensure timely and effective 5 
treatment of health related problems.  6 
For the effectiveness of given national program which focusses on the safe and rational use 7 
of drugs, monitoring of drug use and utilization of collected data for the development, 8 
implementation and evaluation of strategies is essential. The authors strongly believe that through 9 
the implementation of the 12 core WHO interventions [2] the situation might improve, resulting 10 
in more rational prescribing and optimal use of drugs. Future studies should look at the outcomes 11 
of these intervention plans for continuous process improvement. 12 
Strengths 13 
This systematic review fills a significant gap in the literature and has the following main 14 
strengths; 15 
 Coverage of the recent studies on the topic under review. 16 
 Detailed description of patient-care and facility-specific indicators which previous 17 
reviews have not summarized. The results are presented such that greater generalizability 18 
of individual indicators in different regions of the world is apparent.  19 
 The authors have used the published WHO/INRUD indices to systematically compare the 20 
rational use of drugs among different regions of the world.  21 
 The findings from this review provide useful information for researchers, administrators, 22 
policy-makers and other important stakeholders to evaluate existing patterns of drug 23 
utilization at global, regional and national country level.  24 
20 
 
 This systematic review is expected to assist in the formulation of educational 1 
interventions, drug policies and National Essential Drugs Lists (NEDL) as well as 2 
hospital formularies to improve prescribing patterns and the cost-effective use of drugs 3 
nationally and internationally. 4 
Limitations 5 
There are a few limitations to this review.  6 
 Studies reporting the indicators for treatment of illness in populations under 5 years of age 7 
were excluded.  8 
 No interventions and their impacts have been summarized. 9 
 Studies were not differentiated based on private and/or public sector involvement nor 10 
prescriber type. 11 
 A process of meta-analysis was not performed due to the heterogeneity of results in the 12 
included studies. 13 
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